Case Report: Isolated leptomeningeal relapse after systemic control in PALB2-altered pancreatic cancer
- 1Department of General Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 2Cancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China
Abstract
Background: Leptomeningeal metastasis (LM) is an uncommon manifestation of pancreatic ductal adenocarcinoma (PDAC) and has a median survival of only 1–2 months after diagnosis. Isolated LM after prolonged extracranial disease control is particularly rare and may be overlooked when systemic imaging results look stable.
Case presentation: We describe a 51-year-old man with metastatic PDAC who initially received a treatment regimen comprising KN046 and gemcitabine and nab-paclitaxel, followed by a prolonged course of folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), and subsequently underwent conversion surgery with a pathological complete response (ypT0N0, R0). Several months after completing adjuvant FOLFIRINOX, the patient developed a new right lower limb weakness. Brain MRI and cerebrospinal fluid (CSF) cytology results confirmed the presence of isolated LM, but there was no evidence of active extracranial disease. CSF sequencing identified Kirsten rat sarcoma viral oncogene homolog G12D, an AT-rich interaction domain 1A frameshift alteration, and a truncating partner and localizer of BRCA2 p.L920* alteration involving the homologous recombination repair (HRR) pathway. Then, the patient underwent ventriculoperitoneal shunt and Ommaya reservoir placement, followed by treatment with serial intrathecal methotrexate plus dexamethasone and systemic toripalimab with bevacizumab. This multimodal approach was followed by temporary neurological stabilization, but the disease eventually progressed. He survived approximately 30 months since the initial PDAC diagnosis and 3.5 months after LM diagnosis.
Conclusion: Together with our review of 29 published PDAC-LM cases, this report suggests two recurring clinical patterns: fulminant presentation at/or near initial diagnosis and delayed central nervous system (CNS) relapse after prolonged systemic disease control. The repeated detection of Fanconi anemia/homologous recombination repair pathway alterations in several genomically characterized cases gives rise to the possibility that treatment-responsive, HRR pathway–altered PDAC may survive long enough for CNS sanctuary relapse to become clinically apparent. CSF genomic profiling may help characterize rare CNS relapse in molecularly defined PDAC, and new neurological symptoms in long-surviving patients warrant prompt evaluation even when extracranial disease appears controlled.
Related
- Steroid-resistant Relapse of Autoimmune Pancreatitis with Marked Main Pancreatic Duct Dilatation Mimicking Multifocal Pancreatic Cancer
- Preoperative CT Suspicion of Main Pancreatic Duct Injury in Isolated Blunt Pancreatic Trauma: A Case Report With Operative Correlation
- Subjective Sleep Quality in Relation to Relapse Status in Relapsing-Remitting Multiple Sclerosis: A Propensity Score—Matched Nested Case—Control Analysis
- Systemic Medication Adjustment and Short-Term Relapse of Cytomegalovirus Retinitis After Allogeneic Hematopoietic Stem Cell Transplantation: A Research Communication.
- Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma
BibTeX
@article{yuan2026case,
title = {{Case Report: Isolated leptomeningeal relapse after systemic control in PALB2-altered pancreatic cancer}},
author = {Jian Yuan and Yangxian Xu and Qihao Zhou and Guorong Yuan and Meizhen Ye},
journal = {Frontiers in Medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1927688},
url = {https://doi.org/10.3389/fmed.2026.1927688},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Isolated leptomeningeal relapse after systemic control in PALB2-altered pancreatic cancer
AU - Jian Yuan
AU - Yangxian Xu
AU - Qihao Zhou
AU - Guorong Yuan
AU - Meizhen Ye
PY - 2026
DA - 2026/10/12
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1927688
UR - https://doi.org/10.3389/fmed.2026.1927688
AB - Background: Leptomeningeal metastasis (LM) is an uncommon manifestation of pancreatic ductal adenocarcinoma (PDAC) and has a median survival of only 1–2 months after diagnosis. Isolated LM after prolonged extracranial disease control is particularly rare and may be overlooked when systemic imaging results look stable. Case presentation: We describe a 51-year-old man with metastatic PDAC who initially received a treatment regimen comprising KN046 and gemcitabine and nab-paclitaxel, followed by a prolonged course of folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), and subsequently underwent conversion surgery with a pathological complete response (ypT0N0, R0). Several months after completing adjuvant FOLFIRINOX, the patient developed a new right lower limb weakness. Brain MRI and cerebrospinal fluid (CSF) cytology results confirmed the presence of isolated LM, but there was no evidence of active extracranial disease. CSF sequencing identified Kirsten rat sarcoma viral oncogene homolog G12D, an AT-rich interaction domain 1A frameshift alteration, and a truncating partner and localizer of BRCA2 p.L920* alteration involving the homologous recombination repair (HRR) pathway. Then, the patient underwent ventriculoperitoneal shunt and Ommaya reservoir placement, followed by treatment with serial intrathecal methotrexate plus dexamethasone and systemic toripalimab with bevacizumab. This multimodal approach was followed by temporary neurological stabilization, but the disease eventually progressed. He survived approximately 30 months since the initial PDAC diagnosis and 3.5 months after LM diagnosis. Conclusion: Together with our review of 29 published PDAC-LM cases, this report suggests two recurring clinical patterns: fulminant presentation at/or near initial diagnosis and delayed central nervous system (CNS) relapse after prolonged systemic disease control. The repeated detection of Fanconi anemia/homologous recombination repair pathway alterations in several genomically characterized cases gives rise to the possibility that treatment-responsive, HRR pathway–altered PDAC may survive long enough for CNS sanctuary relapse to become clinically apparent. CSF genomic profiling may help characterize rare CNS relapse in molecularly defined PDAC, and new neurological symptoms in long-surviving patients warrant prompt evaluation even when extracranial disease appears controlled.
SN - 2296-858X
ER -